Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
sorry, disregard, old news! Got too excited.
Has this been seen???
07/02/2020 | 04:35am EDT
2 July 2020
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Approval for sale in India
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that its CE-Marked Mologic ELISA1 antibody test has been approved for testing of COVID-19 in India.
Yesterday the Central Drugs Standard Control Organization, part of the Ministry of Health & Family Welfare, published a list of approved Rapid / CLIA / ELISA kits approved for testing of COVID-19, which included Omega's ELISA antibody test.
Approval for sale remains conditional on the submission of supporting technical data and the Company is confident that this submission will be successful, and that Omega will be able to sell its ELISA antibody test directly into this potentially significant target market. The laboratory-based ELISA antibody test has high quality performance data and has been independently validated by the Liverpool School of Tropical Medicine and St George's, University of London.
Whilst the quantum of future sales in unknown at this stage, India is clearly a significant addressable market for COVID-19 antibody testing and Omega will use its direct sales team in India to establish commercial roll-out in the region. The Company expects to update shareholders on first commercial orders as they are received.
Colin King, CEO of Omega commented: "I am delighted that we have received approval to sell the Mologic ELISA antibody test in India as this is a key target market. We have an established direct sales team and we believe a reliable and high-performance antibody test will be very attractive to our laboratory customers. India is one of the fastest growing economies in the world and has a population of over 1.3 billion people. Clearly this is an important market for us to target and I look forward to updating shareholders on our commercial traction."
1 ELISA (Enzyme Linked Immuno-Sorbent Assay) tests are one of the most tested and proven laboratory technologies used by the global diagnostic industry and remain the principle reference point from which rapid diagnostics are coordinated, especially serological tests, including tests for COVID-19.
Ken, I have to thank you for your wise words and information. Thanks mainly to you I have invested more into this stock than any other and it is due to your guidance that I find myself in a happy place! Salute.
We continue to promote our cooperation agreement in front of Covid 19 in conjunction with the social actors of La Carolina Parish.
We share what was the delivery of 2600 masks for health promoters, medical staff, and for all parish communities.
We thank the Parish Board and primary health care techniques for their participation. #ComprometidosConElEcuador #SolGold #MineríaResponsable
Apparently their system cannot take into account off book and overseas trades but you are quoted correctly at the time of purchase/sale so if you are desperate put a dummy trade through but don’t complete!!!
Good progress on building up our lab capacity, with major new manufacturing kit arriving soon. A recruitment drive is ongoing for a significant number of people to run this kit. All on track for 100,000 tests per week capacity in place next month as planned
MHRA pre-approval for self-test usability studies still to come, and we will update investors via RNS when we have it, but timing works well for our production timelines. #odx #covid19
SolGold (LSE & TSX: SOLG) wishes to advise that Mr Craig Jones, the nominee of Newcrest Mining Ltd on the SolGold Board, has today resigned as a Director.
SolGold understands that Mr Jones has resigned as requested at the request of Newcrest. The Board wishes to thank Mr Jones for his contribution to SolGold over the past three years, and wishes him well in his future endeavours.
By order of the Board
Karl Schlobohm
Company Secretary